Management of advanced non-small cell lung cancer: moving towards a more personalised approach
Year: 2012
Type: dissertation
Abstract: Introduction and outline of the thesis 9Part 1: Novel treatment approachesChapter 2: Time for reappraisal of extracranial treatment options? 25 Synchronous brain metastases from non-small cell lung cancer.Chapter 3: Phase I study of concurrent whole brain radiotherapy and 43 erlotinib for multiple brain metastases from non-small cell lung cancer. Chapter 4: Angiogenesis inhibitors in the treatment of NSCLC. 57Chapter 5: A multicenter, phase II study of erlotinib and sorafenib in 79 chemotherapy-naïve patients with advanced non-small cell lung cancer. Part 2: Optimising patient selection and treatment monitoringChapter 6: Fatal interstitial lung disease after erlotinib for non-small 99 cell lung cancer.Case report.Chapter 7: Pulmonary toxicity following bevacizumab and concurrent 107 thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer Chapter 8: Dramatic response to low-dose erlotinib of epidermal growth 117 factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity.Chapter 9: CD133+ circulating hematopoietic progenitor cells predict for 123 response to sorafenib plus erlotinib in non-small cell lung cancer patients.Chapter 10: Dynamic contrast-enhanced CT in patients treated with sorafenib 141 and erlotinib for non-small cell lung cancer: a new method to monitor treatment?Chapter 11: Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer.A Brief Report.
Author: Lind, J.S.W.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W1527750610